Physician profile
Peter A Puzio
NPI 1295795003
$12,223.14
in general payments reported to CMS, 2019-2025
56 companies · $2,723 in 2025
The $2,723 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,466 · 2020: $1,194 · 2021: $217 · 2022: $1,396 · 2023: $2,231 · 2024: $1,995 · 2025: $2,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,949.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,828.79 | 2019-2025 | |
| Biogen, INC. | $805.97 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Ucb, INC. | $766.32 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Lundbeck LLC | $656.52 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $497.06 | 2019-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $425.01 | 2019-2025 | |
| Emd Serono, INC. | $416.02 | 2019-2025 | Mavenclad, Mavenclad |
| Celgene Corporation | $401.22 | 2023-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $360.60 | 2019-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $356.06 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Argenx US, INC. | $355.92 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $354.09 | 2019-2025 | Aimovig, Uplizna |
| Pfizer INC. | $339.69 | 2019-2025 | |
| Sk Life Science, INC. | $278.74 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $266.98 | 2019-2025 | Ultomiris |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $252.59 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Allergan, INC. | $213.69 | 2019-2021 | |
| Lilly USA, LLC | $189.38 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Genzyme Corporation | $188.70 | 2019-2021 | |
| Greenwich Biosciences, INC. | $186.17 | 2019-2020 | |
| Grifols USA, LLC | $180.94 | 2019-2023 | Gamunex-C |
| Mdd US Operations, LLC | $177.30 | 2020-2025 | Gocovri, Gocovri |
| Sunovion Pharmaceuticals INC. | $170.69 | 2019-2020 | |
| Merz North America, INC. | $161.27 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.11 | 2022 | |
| Acorda Therapeutics, INC | $153.46 | 2019-2023 | Inbrija, Ampyra |
| Kyowa Kirin, INC. | $148.42 | 2019-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $141.71 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $139.87 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $133.66 | 2020-2025 | Acthar |
| Tg Therapeutics, INC. | $129.70 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $123.90 | 2022-2025 | |
| Eisai INC. | $114.21 | 2019-2024 | |
| Csl Behring | $111.22 | 2019-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $98.10 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $96.79 | 2024-2025 | Wainua |
| Livanova USA, INC. | $95.92 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| E.R. Squibb & Sons, L.L.C. | $83.23 | 2020-2024 | Zeposia |
| Neurelis, INC. | $80.90 | 2022-2025 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $77.34 | 2021 | |
| Merz Pharmaceuticals, LLC | $73.22 | 2024-2025 | Xeomin |
| Supernus Pharmaceuticals, INC. | $54.93 | 2019-2025 | Qelbree |
| Sumitomo Pharma America, INC. | $52.42 | 2023-2024 | Aptiom |
| Ani Pharmaceuticals, INC. | $50.61 | 2025 | Purified Cortrophin Gel |
| Ipsen Biopharmaceuticals, INC | $41.01 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $35.17 | 2022-2023 | Trudhesa |
| Medtronic, INC. | $34.40 | 2022 | |
| Portola Pharmaceuticals, LLC | $30.92 | 2019 | |
| Springworks Therapeutics, INC. | $22.53 | 2025 | Gomekli |
| Alnylam Pharmaceuticals INC. | $21.97 | 2025 | Onpattro |
| Avion Pharmaceuticals | $19.87 | 2022 | |
| Boston Scientific Corporation | $17.14 | 2019 | |
| Microtransponder, INC. | $15.32 | 2025 | |
| Corium, LLC | $14.33 | 2023 | Adlarity |
| Upsher-Smith Laboratories LLC | $12.06 | 2019 | |
| Adamas Pharmaceuticals, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Puzio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.